By Counterforce Health Team in Elelyso (taliglucerase alfa) —

Do You Qualify for Elelyso (taliglucerase alfa) Coverage by UnitedHealthcare in Florida? Decision Tree & Next Steps

Quick Answer: Your Path to Elelyso Coverage

You likely qualify for Elelyso (taliglucerase alfa) coverage if you have confirmed Type 1 Gaucher disease with enzyme deficiency or genetic testing results. UnitedHealthcare requires prior authorization through OptumRx, often with step therapy (trying preferred ERTs first). Your fastest path: Gather diagnostic labs, document any failed treatments, and submit PA via the UHC Provider Portal. If denied, Florida offers internal appeals (180 days) and external review through the Department of Financial Services (4 months from final denial).

Table of Contents

How to Use This Guide

This decision tree helps you determine your likelihood of getting Elelyso covered by UnitedHealthcare in Florida. Work through each section based on your current situation. Keep your insurance card, recent labs, and any prior treatment records handy.

Before you start: Elelyso treats Type 1 Gaucher disease in patients 4 years and older. The typical dose is 60 units/kg every two weeks via IV infusion. UnitedHealthcare covers this under their medical drug policy but requires prior authorization.

Eligibility Triage: Do You Qualify?

Answer these questions to determine your coverage path:

1. Diagnosis Confirmed?

  • Yes, I have confirmed Type 1 Gaucher disease → Continue to question 2
  • No, but symptoms suggest Gaucher disease → See Possibly Eligible
  • Different type of Gaucher disease → See Not Yet Eligible

2. Required Testing Complete?

  • Beta-glucocerebrosidase enzyme assay showing deficiency → Continue to question 3
  • Genetic testing confirming GBA mutations → Continue to question 3
  • Both completed → Continue to question 3
  • Neither completed → See Possibly Eligible

3. Prior Therapy Status?

  • Never tried other Gaucher ERTs → See Possibly Eligible (step therapy likely required)
  • Failed or couldn't tolerate Cerezyme (imiglucerase) → Continue to question 4
  • Failed or couldn't tolerate VPRIV (velaglucerase alfa) → Continue to question 4
  • Currently on Elelyso and need reauthorization → See Likely Eligible

4. Clinical Documentation Available?

If You're Likely Eligible

You have strong documentation for approval. Here's your action plan:

Document Checklist

Gather these items before submitting your prior authorization:

Required Documentation:

  • ✓ Confirmed Type 1 Gaucher disease diagnosis
  • ✓ Beta-glucocerebrosidase enzyme assay results or genetic testing
  • ✓ Current clinical notes from Gaucher specialist
  • ✓ Documentation of failed/intolerable prior ERTs (if applicable)
  • ✓ Current medication list and insurance information

Supporting Evidence:

  • Recent lab work (CBC, liver function tests, biomarkers like chitotriosidase)
  • Imaging showing organomegaly or bone involvement
  • Progress notes documenting symptoms and treatment goals

Submission Path

Step 1: Contact Your Specialty Pharmacy Most Elelyso patients use specialty infusion centers. Ask your provider to refer you to a UnitedHealthcare-contracted specialty pharmacy.

Step 2: Prior Authorization Submission Your healthcare provider submits PA through:

  • UHC Provider Portal (preferred)
  • OptumRx Specialty Guidance Program: 888-397-8129
  • Fax: Check current number via provider portal

Step 3: Track Status

  • Standard review: 30 days for prospective treatments
  • Expedited review: 72 hours if delay could seriously harm your health
  • Check status via UHC Provider Portal
From our advocates: We've seen Elelyso approvals happen faster when the specialty pharmacy coordinates directly with the prescriber's office. Having all documentation ready before the PA submission prevents delays from requests for additional information.

If You're Possibly Eligible

You meet basic criteria but need additional documentation or testing.

Tests to Request

If missing diagnostic confirmation:

  • Beta-glucocerebrosidase enzyme assay (blood test showing enzyme deficiency)
  • Genetic testing for GBA gene mutations
  • Baseline labs: CBC, comprehensive metabolic panel, liver function tests
  • Biomarkers: Chitotriosidase, CCL18, or glucosylsphingosine levels

What to Track

  • Symptoms: Fatigue, easy bruising, bone pain, enlarged spleen/liver
  • Lab trends: Platelet counts, hemoglobin levels, liver enzymes
  • Prior treatments: Document any previous Gaucher therapies and outcomes

Timeline to Re-apply

  • Diagnostic testing: 2-4 weeks for results
  • Specialist consultation: 4-8 weeks for new patient appointments
  • PA submission: Submit once diagnostic confirmation is complete

Contact a Gaucher specialist through the National Gaucher Foundation to coordinate testing and treatment planning.

If You're Not Yet Eligible

You may need to explore alternatives or prepare for exception requests.

Alternatives to Discuss

  • Step therapy options: Cerezyme (imiglucerase) or VPRIV (velaglucerase alfa)
  • Oral substrate reduction therapy: Cerdelga (eliglustat) for eligible adults
  • Clinical trials: Check ClinicalTrials.gov for Gaucher disease studies

Prepare for Exception Requests

If standard alternatives aren't appropriate:

  • Document contraindications to preferred treatments
  • Gather specialist opinion supporting Elelyso as first-line therapy
  • Prepare medical necessity letter addressing UnitedHealthcare's specific criteria

UnitedHealthcare's step therapy exception process allows exceptions for clinical contraindications or when preferred drugs are inappropriate.

If You've Been Denied

Florida law provides multiple appeal levels with specific timelines and rights.

Choose Your Appeal Path

Internal Appeal (First Level)

  • Deadline: 180 days from denial notice
  • Timeline: 30 days for standard review, 72 hours for expedited
  • Submit via: UHC Provider Portal or mail

Peer-to-Peer Review

  • When: Before formal appeal for outpatient services
  • Deadline: 14 calendar days from denial notice
  • Process: Medical director discusses case with your physician

External Review

  • When: After exhausting internal appeals
  • Deadline: 4 months from final internal denial
  • Submit to: Florida Department of Financial Services
  • Cost: Free to consumers
  • Timeline: Expeditious review, 72 hours for urgent cases

Coverage at a Glance

Requirement Details Source
Prior Authorization Required through OptumRx UHC Provider Portal
Step Therapy May require trial of Cerezyme or VPRIV first UHC Medical Policy
Diagnosis Required Confirmed Type 1 Gaucher disease FDA Label
Age Restriction 4 years and older FDA Label
Site of Care Specialty infusion center or clinic UHC Specialty Drugs

Appeals Playbook for Florida

Level 1: Internal Appeal

Who can file: Patient, authorized representative, or provider How to submit:

  • Online: UHC Provider Portal (verify current link)
  • Mail: Address provided in denial letter
  • Include: Denial letter, additional clinical documentation, medical necessity letter

Level 2: External Review

Managed by: Florida Department of Financial Services Required documents:

  • Final internal denial letter
  • Clinical records supporting medical necessity
  • Physician statement addressing denial reasons

Success tips:

  • Include updated labs (within 90 days)
  • Reference FDA labeling for approved indications
  • Document failed alternatives with specific dates and outcomes

Counterforce Health specializes in turning insurance denials into targeted, evidence-backed appeals. Their platform helps patients and providers identify denial reasons and draft point-by-point rebuttals using the right clinical evidence and payer-specific criteria.

Common Denial Reasons & Solutions

Denial Reason Solution Strategy
"Step therapy not completed" Document failed trials of Cerezyme/VPRIV with dates, doses, and specific reasons for discontinuation
"Not medically necessary" Include specialist letter citing FDA labeling, current symptoms, and treatment goals
"Experimental/investigational" Reference FDA approval for Type 1 Gaucher disease and peer-reviewed evidence
"Quantity limits exceeded" Provide dosing calculation (weight × 60 units/kg) and specialist justification
"Non-formulary drug" Request formulary exception with comparative effectiveness data

Frequently Asked Questions

Q: How long does UnitedHealthcare prior authorization take in Florida? A: Standard review takes up to 30 days. Expedited review (for urgent cases) takes up to 72 hours. Track status via the UHC Provider Portal.

Q: What if Elelyso is non-formulary on my plan? A: You can request a formulary exception. Provide documentation that preferred alternatives are inappropriate or have failed.

Q: Can I request an expedited appeal? A: Yes, if the delay could seriously jeopardize your health. Both internal appeals and external reviews offer expedited timelines (72 hours).

Q: Does step therapy apply if I failed treatments outside Florida? A: Yes, document any prior ERT failures regardless of where treatment occurred. Include medical records and specialist notes.

Q: What's the cost of Elelyso without insurance? A: The wholesale acquisition cost is approximately $839-$899 per 200-unit vial. Pfizer offers patient assistance programs for eligible patients.

Q: Can my doctor do a peer-to-peer review? A: Yes, in Florida, UnitedHealthcare offers peer-to-peer review within 14 days of denial for outpatient services. This must occur before filing a formal appeal.

When navigating complex prior authorization requirements, Counterforce Health's platform can help identify the specific denial basis and generate targeted appeals that address UnitedHealthcare's exact criteria for Elelyso coverage.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Insurance coverage decisions depend on your specific plan and medical circumstances. Always consult with your healthcare provider and insurance company for personalized guidance. For assistance with insurance problems in Florida, contact the Division of Consumer Services at 1-877-MY-FL-CFO (1-877-693-5236).

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.